<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        79-5286-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FROXA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DEFEROXAMINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        90.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MS Pharma " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MS Pharma 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        V03AC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>FROXA </strong>is an injection used to remove excess iron or aluminum from your blood. Desferrioxamine mesylate, the active ingredient in <strong>FROXA</strong>, is a substance called a &lsquo;chelating&rsquo; agent. This means that it binds to the iron and aluminum ions in the blood to form a complex which is then excreted from the body.</p><p>You may have too much iron or aluminum in your blood as a result of iron poisoning or as a side effect of blood transfusion or kidney dialysis. Certain illnesses can also have the same effect.</p><p><strong>FROXA </strong>can also be used to test whether you have certain anemias or diseases affecting the amount of iron in your blood.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Some people MUST NOT take FROXA.&nbsp; Talk to your doctor if:</strong></p><p>You think you may be allergic to <strong>FROXA or</strong> <strong>Desferrioxamine</strong>.</p><p><strong>You should also ask yourself these questions before taking FROXA:</strong></p><p>Are you pregnant or planning to become pregnant? If you become pregnant while you are being treated with <strong>FROXA </strong>you must tell your doctor straight away.</p><p>Are you breast-feeding?</p><p>Do you have any kidney problems or are you on dialysis? Do you have a heart condition?</p><p>Do you have the blood condition thalassemia?</p><p>Is <strong>FROXA </strong>going to be given to a child under the age of 3 years?&nbsp;&nbsp; If it is, the doctor may want to monitor the child&rsquo;s growth regularly</p><p>to make sure it is not being affected&nbsp; by the <strong>FROXA</strong>.</p><p>Has your doctor told you that you have hyperparathyroidism (a condition resulting in excess calcium in the blood and problems with the bones)?</p><p>Has your doctor told you that aluminum has affected your nerves?&nbsp; If so, you may be given a dose of clonazepam before you are given <strong>FROXA</strong>.</p><p>If the answer to any of these questions is YES, tell your doctor or pharmacist because <strong>FROXA</strong></p><p>might not be the right medicine&nbsp; for you.</p><p><strong>Are you taking other medicines?</strong></p><p>Some medicines can interfere with your treatment.&nbsp;&nbsp;&nbsp; Tell your doctor if you are taking any of the following: prochlorperazine, a medicine used to control vertigo or nausea and vomiting, anxiety or schizophrenia erythropoietin (used to treat anemia, particularly in people who are on dialysis)</p><p>Vitamin C.</p><p>Always tell your doctor about all the medicines you are taking.&nbsp;&nbsp; <em>This means medicines you have bought yourself as well as medicines on prescription from your doctor.</em></p><p><strong>Will there be any problems with driving or using machinery?</strong></p><p><strong>FROXA </strong>can make you feel dizzy or drowsy. It can also affect your vision or hearing. You must not drive, operate machinery or do anything else which requires concentration until you know how your medicine affects you.</p><p><strong>Other special warnings</strong></p><p><strong>Medical check-ups while you are using FROXA</strong></p><p>If you use <strong>FROXA </strong>for a long time or you have kidney problems and are on dialysis, your doctor may want to give you regular eye tests and hearing tests. This is because <strong>FROXA </strong>can affect your vision and your hearing. These tests are usually done every 3 months.</p><p><strong>Children</strong></p><p>In children under the age of 3 years, high doses of <strong>FROXA </strong>may affect growth. Regular checks on body weight and height are, therefore, recommended in children using <strong>FROXA</strong>.&nbsp; These checks are usually done every 3 months.</p><p><strong>X-rays or scans</strong></p><p>The results may be affected by treatment with <strong>FROXA</strong>. Make sure that the doctor or nurse knows that you are being treated with <strong>FROXA </strong>if an X-ray or scan is suggested.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The doctor will have decided what dose of <strong>FROXA </strong>you need and when you should&nbsp; take it. The dose will be on the pharmacist&rsquo;s label. Check the label carefully. If you are not sure, ask your doctor or pharmacist.</p><p>A doctor or nurse may prepare your injection for you, or you may be taught how to do this yourself. The <strong>FROXA </strong>powder should be dissolved in the &lsquo;water for injection&rsquo; that your pharmacist has given you.</p><p>&nbsp;</p><p>Treatment with the solution should start within 3 hours of the vial being reconstituted. If the solution has been prepared under sterile conditions (for instance in a hospital), it may be stored at room temperature (25oC or below) for up to 24 hours before being used. Any unused <strong>FROXA </strong>injection should be thrown away.</p><p><strong>Ways in which FROXA can be given</strong></p><p><strong>FROXA </strong>can be given in different ways, for example:</p><p>By injection into a muscle.&nbsp;&nbsp; This is called being given intramuscularly.</p><p>By injection into a vein.&nbsp; This is called being given intravenously. It should be given slowly over a period rather than all in one go. This is called a slow infusion.</p><p>By injection under your skin.&nbsp;&nbsp; This is called being given subcutaneously.&nbsp; It may be given over a period using a special pump.&nbsp;&nbsp; This is called an infusion.</p><p>The dose that you need will depend on why you have to take <strong>FROXA</strong>. Your doctor will work out exactly how much <strong>FROXA </strong>you need. This is especially important if you have low serum ferritin levels or acute iron intoxication.</p><p>The usual doses and ways of taking <strong>FROXA </strong>are as follows:</p><p><strong>Iron Poisoning Treatment</strong></p><p>To treat iron poisoning FROXA<strong> </strong>is usually given intravenously (injected into the vein).&nbsp; The recommended dose is 15 mg/kg body weight every hour. This may be reduced after 4 to 6 hours. The maximum recommended dose is 80 mg/kg body weight every 24 hours.</p><p><strong>FROXA&nbsp; </strong>may also be given intramuscularly (injected&nbsp; into the muscle).&nbsp;&nbsp; The recommended dose if <strong>FROXA </strong>is given like this is 2 g for an adult or 1 g for a child.&nbsp; This is usually given in a single injection.</p><p><strong>Iron Overload Treatment</strong></p><p>Your doctor will work out exactly how much <strong>FROXA </strong>you will need. This will depend on how much extra iron you have in your body. <strong>FROXA </strong>is usually given subcutaneously (a slow injection under the skin). It can sometimes be given intramuscularly (injected into the muscle) though. The dose is usually between 20 and 60 mg/kg body weight. It is usually given between 5 and 7 times a week, depending on how much extra iron you have got in your body. In children under 3 years of age, the average daily dose is not usually more than 40 mg/kg.</p><p><strong>Aluminum Overload Treatment</strong></p><p><strong>FROXA </strong>is usually given by slow intravenous injection.</p><p>The exact dose of <strong>FROXA </strong>that you need will depend on how much extra aluminum you have in your body. Your&nbsp; doctor&nbsp; will do tests to work this out.</p><p>If you are on dialysis, the usual dose of <strong>FROXA </strong>is 5 mg/kg body weight. This is normally given once a week.&nbsp; When you are given, your <strong>FROXA </strong>will depend on how much extra aluminum you have in your body. It will either be given during the last 60 minutes of your dialysis or 5 hours before your dialysis starts.</p><p>If you are on peritoneal dialysis (CAPD&nbsp; or&nbsp; CCPD),&nbsp; the&nbsp; usual&nbsp; dose&nbsp; of&nbsp; <strong>FROXA&nbsp; </strong>is,&nbsp; again,&nbsp; 5 mg/kg&nbsp; body&nbsp; weight. This is normally given once a week. Usually the <strong>FROXA </strong>is mixed with the fluid in your dialysis bag.&nbsp; However, it can also be given by any of the other ways listed above.</p><p><strong>Testing to see if you have got too much iron in your body</strong></p><p><strong>FROXA </strong>is usually given intramuscularly (injected into a muscle). The usual dose is 500 mg. After you have had your <strong>FROXA</strong>, your doctor or nurse will probably want you to collect urine samples for about 6 hours. They will then do tests on your urine to see how much iron is in it.</p><p><strong>Testing to see if you have got too much aluminum in your body if you are on dialysis</strong></p><p>Your doctor or nurse will probably take a blood sample from you before you are given <strong>FROXA</strong>.</p><p>This will be taken just before your dialysis. Tests will be done on the blood to see how much aluminum is in it.</p><p>The usual dose of <strong>FROXA </strong>is 5 mg/kg body weight. It is usually given by slow intravenous infusion (slow injection into a vein) during the last hour of dialysis.</p><p>Another&nbsp; blood test will probably&nbsp; be taken before your next session&nbsp; of hemodialysis to check how much aluminum&nbsp; is in your blood.</p><p><strong>Use in older patients</strong></p><p><strong>FROXA </strong>is used in older patients at the same doses as for other adults.</p><p><strong>What if you have had too much FROXA? (Overdose)</strong></p><p>If you think you have either been given or have taken too much <strong>FROXA </strong>tell your doctor or nurse straight away.&nbsp;&nbsp; If you think you have either been given it or have taken it too often, also tell your doctor or nurse straight away.</p><p><strong>What if you miss a dose of FROXA?</strong></p><p>If you miss one of your appointments, please let your doctor or nurse know immediately.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Most people who are prescribed <strong>FROXA </strong>will benefit from using it. As with all other medicines though, it can cause side effects in some people.</p><p>Do not be alarmed&nbsp; by this list of possible&nbsp; side effects. You may not experience any of them. Your urine may turn a reddish-brown color.&nbsp; This is because there is more iron in your urine. This is usually nothing to worry about, but if you are worried, you should talk to your doctor or nurse.</p><p><strong>Some side effects can be serious</strong></p><p><strong>Stop taking FROXA and tell your doctor straight away if you notice:</strong></p><p>Bronchospasm or tightness of chest with wheezing or coughing and difficulty in breathing.If you feel faint, (you might&nbsp; have low blood&nbsp; pressure),&nbsp; have a rash, or experience itching, difficulty&nbsp; breathing&nbsp; or facial&nbsp; and throat swelling.&nbsp;&nbsp; These&nbsp; might&nbsp; be the&nbsp; result&nbsp; of an allergic reaction&nbsp; which&nbsp; is very rare (likely&nbsp; to affect fewer than 1 in 10,000&nbsp; patients).</p><p>If&nbsp; you&nbsp; notice,&nbsp; severe&nbsp; decrease&nbsp; of&nbsp; urine&nbsp; output&nbsp; (sign&nbsp; of&nbsp; kidney&nbsp; problem)&nbsp; or&nbsp; experience convulsion (reported&nbsp; mainly&nbsp; in patients on&nbsp; dialysis).&nbsp; Those side effects were reported with unknown frequency.</p><p>&nbsp;</p><p><strong>Important information if you get an infection while you are taking FROXA</strong></p><p>If you start to feel feverish with a sore throat or stomach pains or general discomfort or develop shortness of breath while you are taking <strong>FROXA</strong>, you must seek medical advice immediately. This is because people who have iron or aluminum overload are more vulnerable to certain types of infection.&nbsp;&nbsp; If you get an infection, your doctor may want you to do some tests and give you</p><p>Some medicines to treat the infection.&nbsp;&nbsp; You may also have to stop using <strong>FROXA </strong>until any infections clear up.</p><p><strong>It is very common </strong>(more than 10% of people) to develop pain, swelling, redness, a rash, itch or scabbing at the <strong>FROXA </strong>injection site. Less frequently blisters and a burning sensation might be experienced. Aching muscles or joints in the arms or legs is also very common.</p><p><strong>The side effects listed below have also been reported. Up to 1 in 10 people have experienced</strong></p><p>Headache, nausea (feeling sick) or fever Itchy rash Changes in their bones, slowing down of growth (especially in children under 3).</p><p><strong>Up to 1 in 100 people have experienced:</strong></p><p>Vomiting, stomach pains Asthma</p><p>Problems with their ears such as tinnitus and deafness.</p><p><strong>Up to 1 in 1,000 people have experienced:</strong></p><p>Problems with their eyes such as blurred vision, impaired or loss of vision, not being able to see colors as well (color blindness), not being able to see at night (night blindness), blind spots, changes in the retina, cataracts (cloudy lenses), cloudiness on the front of the eye (or cornea) Low blood pressure (light-headedness, dizziness, faintness).&nbsp;&nbsp; This can happen if <strong>FROXA </strong>is not given correctly. Increased&nbsp; risk of getting certain infections.</p><p><strong>Up to 1 in 10,000 people have experienced:</strong></p><p>Skin rash covering most of the body</p><p>A serious condition which causes severe breathing problems called Acute Respiratory Distress Syndrome</p><p>Diarrhea</p><p>Changes in the blood which can make you look pale or cause tiredness, headaches, nosebleeds, dizziness or being short of breath when exercising. You might also get more frequent viral infections (fever, chills, sore throat or mouth ulcers), or find that you bleed or bruise more easily than normal.</p><p>Stomach and gut infections.</p><p>Other effects such as dizziness,&nbsp; loss of feeling in their hands, feet, arms or legs, numbness&nbsp; or tingling&nbsp; (pins and needles).</p><p>In patients on dialysis:&nbsp; personality changes, headache, confusion, paralysis of part or all of the body, stiff neck, abnormal, speech and eye movements.</p><p><strong>Frequency not known </strong>(cannot be estimated from the available data). Muscle spasms Abnormal liver or renal function test results</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The vials of <strong>FROXA </strong>powder before they are made up into the injection should not be stored above 30&deg;C.</p><p>Each vial is for single use only.</p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use <strong>FROXA </strong>after the expiry date which is printed on the outside of the pack.</p><p>Do not throw away any medicines via wastewater or household waste. Ask you pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>FROXA </strong>is available in clear glass vials containing either 500 mg of <strong>Desferrioxamine</strong> mesylate. Packs contain either ten 500 mg vials.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                FROXA is available in clear glass vials containing either 500 mg of Desferrioxamine mesylate. Packs contain either ten 500 mg vials.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi, Riyadh, Kingdome Saudi Arabia. info-ksa@mspharma.com</p><p><strong>Manufacturer by:</strong></p><p>MS Pharma - Jordan for MS Pharma-Saudi.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Sep,2021 
SPM-14-0024

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>فروكسا هو حقنة تستخدم لإزالة الحديد الزائد أو الألمنيوم من الدم.</strong></p><p dir="RTL">ديفيروكسامين ميسايلات، العنصر النشط في فروكسا، هو مادة تسمى &lt;&lt; عامل الاستخلاب&gt;&gt; ، وهذا يعنى أنها ترتبط بأيونات الحديد والألمنيوم في الدم لتشكل مركب ثم تفرز من الجسم.</p><p dir="RTL">قد يكون لديك الكثير من الحديد أو الألمنيوم في الدم نتيجة لتسمم الحديد أو كجانب تأثير نقل الدم أو غسيل الكلى، بعض الأمراض يمكن أن يكون لها نفس التأثير.</p><p dir="RTL">يمكن أيضا أن تستخدم فروكسا لاختبار ما إذا كان لديك بعض الأنيميا أو الأمراض التي تؤثر على كمية الحديد في دمك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>فروكسا هو حقنة تستخدم لإزالة الحديد الزائد أو الألمنيوم من الدم.</strong></p><p dir="RTL"><strong>بعض الناس يجب ألا تأخذ فوركسا تحدث مع طبيبك إذا:</strong></p><p dir="RTL">تظن أنك قد تكون لديك حساسية من فروكسا أو ديفيروكسامين</p><p dir="RTL">يجب عليك أيضا أن تسأل نفسك هذه الأسئلة قبل أخذ فروكسا:</p><p dir="RTL">- هل أنت حامل أو تخططين للحمل؟ إذا أصبحت حاملًا أثناء وجودك يجب عليك إخبار طبيبك فوراً.</p><p dir="RTL">- هل ترضعين؟ هل لديك أي مشاكل في الكلى أو هل أنت تقوم بعمل غسيل الكلى؟</p><p dir="RTL">- هل تعاني من مرض في القلب؟</p><p dir="RTL">- هل تعاني من مرض الثلاسيمبا في الدم؟</p><p dir="RTL">- هل سيتم إعطاء فروكسا لطفل تحت سن 3 سنوات؟ إذا كان كذلك، قد يرغب الطبيب لمراقبة نمو الطفل بانتظام للتأكد من عدم تأثره بفروكسا.</p><p dir="RTL">- هل أخبرك طبيبك أن لديك فرط نشاط جارات الدرقية &nbsp;&lt;28 حالة نتجت عن ذلك الكالسيوم الزائد في الدم ومشاكل العظام.؟</p><p dir="RTL">- هل أخبرك طبيبك أن الألمنيوم قد أثر على أعصابك؟ إذا كان الأمر كذلك، قد يتم منحك جرعة من كلونازيبام قبل أن يتم منحك فروكسا</p><p dir="RTL">- إذا كانت الإجابة على أي من هذه الأسئلة نعم، أخبر طبيبك أو الصيدلي لأن فروكسا قد لا يكون الدواء المناسب لك</p><p dir="RTL"><strong>هل تتناول أدوية أخرى؟</strong></p><p dir="RTL">يعض الأدوية يمكن أن تتداخل مع علاجك، أخبر طبيبك إذا أنت تأخذ أي من التالية:</p><p dir="RTL"><strong>- </strong>Prochlorperazine دواء يستخدم للسيطرة على الدوار أو الغثيان والقيء أو القلق<strong> او انفصام في الشخصية، </strong>Erythropoietin يستخدم لعلاج فقد الدم، وخاصة في الأشخاص الذين يستخدمون غسيل الكلى</p><p dir="RTL"><strong>- </strong>فيامين سي</p><p dir="RTL"><strong>أخبر طبيبك دائما عن جميع الأدوية التي تتناولها، هذا يعنى الأدوية التي لديك واشتريتها بنفسك وكذلك الأدوية على وصفة طبية من الدكتور الخاص بك.</strong></p><p dir="RTL"><strong>هل سيكون هناك أي مشاكل في القيادة أو استخدام الآلات؟</strong></p><p dir="RTL">فروكسا يمكن أن يجعلك تشعر بالدوار أو النعاس، يمكن أن يؤثر أيضًا على الرؤية أو السمع، يجب عليك ألا تقود السيارة وكذلك تشغيل الآلات أو القيام بأي شيء آخر يتطلب التركيز حتى تعرف كيف يؤثر الدواء الخاص بك عليك.</p><p dir="RTL"><strong>تحذيرات خاصة أخرى</strong></p><p dir="RTL">- الفحوصات الطبية أثناء استخدام فروكسا</p><p dir="RTL">إذا كنت تستخدم فروكسا لفترة طويلة أو لديك مشاكل في الكلى وغسيل الكلى، قد يرغب طبيبك في عمل اختبارات السمع، هذا لأن فروكسا يمكن أن يؤثر على الرؤية والاستماع، عادة ما يتم إجراء هذه الاختبارات كل 3 أشهر.</p><p dir="RTL">- الأطفال</p><p dir="RTL">- في الأطفال دون سن 3 سنوات، قد تؤثر الجرعات العالية من فروكسا على النمو، لذا يوصى بالقيام بفحوصات&nbsp; منتظمة بوزن الجسم والطول عند الأطفال الذين يستخدمون فروكسا الفحوصات الطبية هي عادة ما تتم كل 3 أشهر.</p><p dir="RTL">- الأشعة السينية أو المسح الضوئي</p><p dir="RTL">- قد تتأثر النتائج من خلال العلاج مع فروكسا تأكد من أن الطبيب أو الممرضة يعرض أنك تعالج ب فروكسا إذا تم اقتراح أشعة سينية أو &nbsp;مسح ضوئي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>سوف يقرر الطبيب جرعة فروكسا التي تحتاجها ومتى يجب أن تأخذها، ستكون الجرعة على ملصق الصيدلي، تحقق من الملصق بعناية، إذا كنت غير متأكد، فاسأل عنه طبيب أو صيدلي.</strong></p><p dir="RTL">قد يقوم الطبيب أو الممرضة بإعداد حقنة لك، أو قد يتم تعليمك كيفية القيام بذلك بنفسك، يجب تذويب مسحوق فروكسا في &lt;&lt;الماء للحقن&gt;&gt; الذي أعطاك إياه الصيدلي.</p><p dir="RTL">يجب أن يبدأ العلاج مع المحلول في غضون 3 ساعات من بدء تكوين العبوة. إذا كان الحل قد تم إعداده تحت ظروف معقمة (على سبيل المثال في المستشفى)، قد يتم تخزينها في درجة حرارة الغرفة (25 درجة مئوية أو أقل) لمدة تصل إلى 24 ساعة قبل استخدامها، وأي &nbsp;حقن الفروكسا الغير المستخدمة يجب التخلص منها بعيدًا.</p><p dir="RTL"><strong>الطرق التي يمكن من خلالها إعطاء فروكسا</strong></p><p dir="RTL">يمكن إعطاء فروكسا بطرق مختلفة، على سبيل المثال/</p><p dir="RTL">عن طريق الحقن في العضلات، وهذا ما يسمى معطى في العضل.</p><p dir="RTL">- عن طريق الحقن في الوريد، وهذا ما يسمى بالحقن الوريدي، يجب أن تعطى ببطء على مدى فترة بدلًا من كل دفعة واحدة.</p><p dir="RTL">هذا ما يُسمى تسريب بطيء.</p><p dir="RTL">- عن طريق الحقن تحت الجلد، وهذا ما يسمى تحت الجلد، قد يعطى خلال فترة باستخدام مضخة خاصة، يسمى هذا بالتسريب.</p><p dir="RTL">تعتمد الجرعة التي تحتاجها على السبب الذي يجعلك تأخذ فروكسا، سيحدد طبيبك بالضبط مقدار فروكسا الذي تحتاجه ، هذا مهم بشكل انخفاض مستويات الفيريتين في الدم أو تسمم الحديد الحاد.</p><p dir="RTL"><strong>الجرعات المعتادة وطرق أخذ فروكسا هي كما يلي:</strong></p><p dir="RTL">- علاج التسمم بالحديد</p><p dir="RTL">لعلاج التسمم بالحديد عادة ما يتم إعطاء فروكسا عن طريق الوريد (حقنة في الوريد). الجرعة الموصي بها هي 15 ملغم/ كغم من وزن الجسم كل ساعة. قد يتم تخفيض هذا بعد 4 إلى 6 ساعات، الجرعة القصوى الموصي بها هي 80 ملغم / كغم من وزن الجسم كل 24 ساعة.</p><p dir="RTL">يمكن أيضا إعطاء فروكسا العضلي (حقنة في العضلة). الجرعة الموصى بها إذا تم إعطاء فروكسا مثل هذه الحالة هي 2 غرام لشخص بالغ أو 1 غرام لطفل، هذا عادة ما يعطى في حقنة واحدة.</p><p dir="RTL">- علاج الحديد الزائد</p><p dir="RTL">سيقوم الطبيب بتحديد كمية فروكسا التي ستحتاجها بالضبط، سيعتمد هذا على كمية الحديد الزائدة &nbsp;في جسمك.</p><p dir="RTL">عادة ما يتم إعطاء فوركسا تحت الجلد (حقن بطيء تحت الجلد)، ويمكن في بعض الأحيان أن يعطى في العضل (حقنة في العضلات) رغم ذلك، الجرعة عادة ما بين 20 و 60 ملغم / كغم من وزن الجسم، وعادة ما تعطى بين 5 و 7 مرات في الأسبوع، اعتماداً على كمية الحديد الإضافية التي لديك في جسمك، في الأطفال دون سن 3 سنوات من العمرـ لا يتجاوز متوسط الجرعة اليومية عادة أكثر من 40 ملغم / كغم.</p><p dir="RTL">- معالجة الألمنيوم الزائد</p><p dir="RTL">- عادة ما يتم إعطاء فروكسا عن طريق الحقن البطيء في الوريد.</p><p dir="RTL">تعتمد الجرعة الدقيقة من فروكسا التي تحتاجها على كمية الألمنيوم الإضافية الموجودة في جسمك، سيقوم الطبيب بإجراء اختبارات لعمل ذلك.</p><p dir="RTL">إذا كنت تقوم بعمل غسيل الكلى، فإن الجرعة المعتادة من فروكسا هي 5 ملغم/ كلغم من وزن الجسم، هذه عادة ما يعطى مرة في الأسبوع عندما ، تعتمد فروسكا على كمية الألمنيوم التي تحتاجها في جسمك، سيتم إعطاؤك خلال 1575 u إلى 60 دقيقة الأخيرة لغسيل الكلى أو 5 ساعات قبل أن يبدأ غسيل الكلى</p><p dir="RTL">إذا كنت تخضع لغسيل الكلى البريتوني CCPD) أو (CAPD الجرعة المعتادة من فروكسا هي ، 5 ملغم / كلغم من وزن الجسم. يتم إعطاء هذا عادة مرة واحدة في الأسبوع. عادة ما يتم خلط فروكسا بالسائل الموجود في كيس غسيل الكلى. ومع ذلك ، يمكن أيضًا تقديمها بأي من الطرق الأخرى المذكورة أعلاه.</p><p dir="RTL">- اختبار لمعرفة ما إذا كان لديك نسبة عالية من الحديد في جسمك</p><p dir="RTL">عادة ما يتم إعطاء فروكسا العضلي (حقنة في العضلة)، الجرعة المعتادة هي 500 ملغم.</p><p dir="RTL">بعد حصولك على فروكسا، قد يرغب الطبيب أو الممرضة في جمع عينات البول لمدة 6 ساعات، ثم يقومون بإجراء اختبارات على البول لمعرفة كمية الحديد الموجودة فيه.</p><p dir="RTL">- اختبار لمعرفة ما إذا كان لديك نسبة كبيرة من الألمنيوم في جسمك إذا كنت تقوم بعمل غسيل الكلى من المحتمل أن يأخذ الطبيب أو الممرض عينة دم منك قبل إعطاءك فروكسا، سيتم أخذ هذا قبل غسيل الكلى مباشرة. سيتم إجراء اختبارات على الدم لمعرفة كمية الألمنيوم الموجودة فيه..</p><p dir="RTL">الجرعة المعتادة من فروكسا هي 5 ملغم / كغم من وزن الجسم، وعادة ما تعطى عن طريق الوريد البطيء التسريب (حقن بطيء في الوريد) خلال الساعة الأخيرة من غسيل الكلى.</p><p dir="RTL">من المحتمل أن يتم إجراء فحص دم آخر قبل الجلسة التالية من غسيل الكلى للتأكد من كم من الألمنيوم في دمك.</p><p dir="RTL"><strong>- </strong><strong>استخدام في المرضى كبار السن</strong></p><p dir="RTL">يستخدم فروكسا في المرضى كبار السن في نفس الجرعات كما للبالغين الآخرين.</p><p dir="RTL"><strong>ماذا لو تناولت الكثير من فروكسا؟ (جرعة مفرطة)</strong></p><p dir="RTL">إذا كنت تعتقد أنك قد أعطيت أو أخذت الكثير من فروكسا أخبر طبيبك أو الممرضة على الفور، إذا كنت تعتقد أنه قد تم إعطاؤه لك أو تناولته كثيرًا ، أخبر طبيبك أو ممرضتك على الفور.</p><p dir="RTL"><strong>ماذا لو نسيت جرعة من فروكسا؟</strong></p><p dir="RTL">إذا فاتتك إحدى الجرعات، يرجى إخبار الطبيب أو الممرضة على الفور.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">معظم الناس الذين تم وصفهم فروكسا سيستفيدون من استخدامه. كما هو الحال مع جميع الأدوية الأخرى على الرغم من ذلك، يمكن أن يسبب آثارًا جانبية لدى بعض الأشخاص.</p><p dir="RTL">لا تنزعج من هذه القائمة من الآثار الجانبية المحتملة. قد لا تواجه أيًا منها. قد يتحول لون البول إلى اللون البني المحمر. هذا لأن هناك المزيد من الحديد في البول.هذا الأثر عادة يحدث فلا داعي للقلق، ولكن إذا كنت قلقًا، فعليك التحدث إلى طبيبك أو الممرض</p><p dir="RTL"><strong>بعض الآثار الجانبية يمكن أن تكون خطيرة</strong></p><p dir="RTL"><strong>توقف عن تناول فروكسا وأخبر طبيبك فورًا إذا لاحظت:</strong></p><p dir="RTL">-تشنج قصبي أو ضيق في الصدر مع أزيز أو السعال وصعوبة في التنفس.</p><p dir="RTL">-إذا شعرت بالإغماء، (قد يكون لديك ضغط دم منخفض) أو تعاني من طفح جلدي أو تعاني من الحكة، صعوبة في التنفس أو تورم الوجه والحلق. قد تكون هذه نتيجة لحساسية رد الفعل الذي هو نادر جدًا (من المحتمل أن يؤثر على أقل من 1 في 10000 مريض).</p><p dir="RTL">-إذا لاحظت، انخفاض شديد في خروج البول (علامة على مشكلة في الكلى) أو حالة التشنج (ذكرت بشكل رئيسي في المرضى على غسيل الكلى)، تم الإبلاغ عن هذه الآثار الجانبية مع تكرار غير معروف.</p><p dir="RTL"><strong>معلومات مهمة في حالة الإصابة بعدوى أثناء استخدام فروكسا.</strong></p><p dir="RTL">إذا بدأت تشعر بالحمى مع ألم في الحلق أو آلام في المعدة أو عدم راحة بشكل عام أو تطور ضيق في التنفس أثناء أخذ فروكسا، يجب عليك طلب المشورة الطبية على الفور، وذلك لأن الأشخاص الذين لديهم زيادة في الحديد أو الألومنيوم أكثر عرضة لأنواع معينة من العدوى. إذا أصبت بالعدوى، فقد يطلب منك الطبيب إجراء بعض الاختبارات وإعطائك بعض الأدوية لعلاج العدوى. قد تضطر أيضًا إلى التوقف عن استخدام فروكسا حتى تكون العدوى واضحة.</p><p dir="RTL">&nbsp;من الشائع جدًا (أكثر من 10% من الناس) أن يصابوا بألم وتورم واحمرار وطفح جلدي وحكة أو تقشر في موقع الحقن فروكسا. في كثير من الأحيان قد تكون هناك بثور وإحساس حارق. كما أن آلام العضلات أو المفاصل في الذراعين أو الساقين شائعة جدًا</p><p dir="RTL"><strong>كما تم الإبلاغ عن الآثار الجانبية المذكورة أدناه.</strong></p><p dir="RTL"><strong>شخص واحد من كل 10 أشخاص ما يلي:</strong></p><p dir="RTL">الصداع، الغثيان (الشعور بالغثيان) أو الحمى الطفح المثير للحكة، تباطؤ النمو (خاصة عند الأطفال أقل من 3 سنوات).</p><p dir="RTL"><strong>شخص واحد من كل 100 شخص بما يلي:</strong></p><p dir="RTL">-القيء وآلام المعدة</p><p dir="RTL">-الربو</p><p dir="RTL">-مشاكل مع آذانهم مثل طنين الأذن .</p><p dir="RTL"><strong>شهد 1 من كل 1000 شخص ما يلي:</strong></p><p dir="RTL">مشاكل في عيونهم مثل عدم وضوح الرؤية أو ضعف البصر أو عدم القدرة على الرؤية الألوان أيضًا (عمى الألوان)، وعدم القدرة على الرؤية في الليل (العمى الليلي)، والبقع العمياء، التغيرات في الشبكية، إعتام عدسة العين (العدسات الغائمة)، غيوم &quot;تغبيش&quot; في مقدمة العين (أو القرنية) انخفاض ضغط الدم (خفة في الرأس ، دوار ، ضعف). يمكن أن يحدث هذا إذا لم يتم إعطاء FROXA بشكل صحيح. زيادة خطر الإصابة بعدوى معينة.</p><p dir="RTL"><strong>شهد 1 من كل 10،000 شخص ما يلي:</strong></p><p dir="RTL">طفح جلدي يغطي معظم الجسم</p><p dir="RTL">حالة خطيرة تسبب في مشاكل شديدة في التنفس تسمى &quot; متلازمة الضائقة التنفسية الحادة &quot;</p><p dir="RTL">إسهال</p><p dir="RTL">التغييرات في الدم والتي يمكن أن تجعلك تبدو شاحبًا أو تسبب التعب، والصداع، ونزيف الأنف، الدوخة أو قصر التنفس عند ممارسة الرياضة. قد قد تصاب أيضًا بالعدوى الفيروسية بشكل متكرر (الحمى، القشعريرة، التهاب الحلق أو قرح الفم)، أو العثور على نزيف أو كدمات أكثر سهولة من المعتاد.</p><p dir="RTL">المعدة و التهابات القناة الهضمية.</p><p dir="RTL">آثار أخرى مثل الدوخة، وفقدان الشعور في أيديدهم والقدمين والذراعين أو الساقين، خدر أو وخز (دبابيس وإبر).</p><p dir="RTL">في مرضى غسيل الكلى: تغيرات في الشخصية ، صداع ، ارتباك ، شلل في جزء أو كل الجسم ، تيبس الرقبة ، حركات غير طبيعية ، كلام وحركات العين.</p><p dir="RTL"><strong>تكرار غير معروف (لا يمكن تقديره من البيانات المتاحة).</strong></p><p dir="RTL">&nbsp;تشنجات عضلية</p><p dir="RTL">نتائج غير طبيعية لفحص الكبد أو وظائف الكلى</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب عدم تخزين عبوة مسحوق فروكسا قبل تحضيرها للحقن فوق 30 درجة مئوية.</p><p dir="RTL">كل عبوة للاستخدام الفردي فقط. ابق هذا الدواء بعيدًا عن متناول الأطفال&nbsp; لا تستخدم فروكسا بعد تاريخ انتهاء الصلاحية الذي تتم طباعته على الجزء الخارجي من العبوة. لا تتخلص من أي أدوية عن طريق مياة الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي كيف تتخلص من الأدوية التي لم تعد تستخدمها. هذه التدابير سوف تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">فروكسا متوفر في قارورة زجاجية شفافة تحتوي إما على 500 ملغم من ديفيروكسامين<strong> </strong>ميسيلت.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">فروكسا متوفر في قارورة زجاجية شفافة تحتوي إما على 500 ملغم من ديفيروكسامين<strong> </strong>ميسيلت.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إم إس فارما السعودية الرياض، المملكة العربية السعودية.</p><p dir="RTL">info-ksa@mspharma.com</p><p dir="RTL"><strong>صنعت بواسطة:</strong></p><p dir="RTL">إم إس فارما-الأردن لصالح إم أس فارما &ndash; المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            سبتمبر
SPM-14-0024

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Froxa® Powder for reconstitution for subcutaneous, intramuscular or intravenous administration
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Material name	Quantity
Used/ Vial 
Deferoxamine Mesylate	500 mg
Water for Injection*	Qs
                     Total Volume: 3 ml(Before lyophilisation)
*(Disappeared during the lyophilisation process)

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for reconstitution for subcutaneous, intramuscular or intravenous administration
White to off white lyophilized powder . 


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment for chronic iron overload, e.g.</p><p>&bull; Transfusional haemosiderosis in patients receiving regular transfusions e.g. thalassaemia major</p><p>&bull; primary and secondary haemochromatosis in patients in whom concomitant disorders (e.g. severe anaemia, hypoproteinaemia, renal or cardiac failure) preclude phlebotomy.</p><p>Treatment for acute iron poisoning.</p><p>For the diagnosis of iron storage disease and certain anaemias.</p><p>Aluminium overload - In patients on maintenance dialysis for end stage renal failure where preventative measures (e.g. reverse osmosis) have failed and with proven aluminium-related bone disease and/or anaemia, dialysis encephalopathy; and for diagnosis of aluminium overload .</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Froxa may be administered parenterally.</p><p><em>For parenteral administration</em>:</p><p>The drug should preferably be employed in the form of a 10% solution, e.g. 500 mg: by dissolving the contents of one 500mg vial in 5ml of water for injection. When administered subcutaneously the needle should not be inserted too close to the dermis. The 10% Froxa solution can be diluted with routinely employed infusion solutions (saline, glucose, dextrose or dextrose-saline), although these should not be used as solvent for the dry substance. Dissolved Froxa can also be added to dialysis fluid and given intraperitoneally to patients on continuous ambulatory peritoneal dialysis (CAPD) or continuous cyclic peritoneal dialysis (CCPD).</p><p>Only clear pale yellow Froxa solutions should be used. Opaque, cloudy or discoloured solutions should be discarded. Heparin is pharmaceutically incompatible with Froxa solutions.</p><p><strong>Treatment of acute iron poisoning</strong></p><p><em>Adults and children: </em></p><p>Froxa may be administered parenterally. Froxa is an adjunct to standard measures generally used in treating acute iron poisoning. It is important to initiate treatment as soon as possible.</p><p>Parenteral Froxa treatment should be considered in any of the following situations:</p><p>&bull; all symptomatic patients exhibiting more than transient minor symptoms (e.g. more than one episode of emesis or passage of one soft stool),</p><p>&bull; patients with evidence of lethargy, significant abdominal pain, hypovolaemia, or acidosis,</p><p>&bull; patients with positive abdominal radiograph results demonstrating multiple radio-opacities (the great majority of these patients will go on to develop symptomatic iron poisoning),</p><p>&bull; any symptomatic patient with a serum iron level greater than 300 to 350 micro g/dL regardless of the total iron binding capacity (TIBC). It has also been suggested that a conservative approach without Froxa therapy or challenge should be considered when serum iron levels are in the 300 to 500 micro g/dL range in asymptomatic patients, as well as in those with self-limited, non-bloody emesis or diarrhoea without other symptoms.</p><p>The dosage and route of administration should be adapted to the severity of the poisoning.</p><p><em>Dosage:</em></p><p>The continuous intravenous administration of Froxa is the preferred route and the recommended rate for infusion is 15 mg/kg per hour and should be reduced as soon as the situation permits, usually after 4 to 6 hours so that the total intravenous dose does not exceed a recommended 80 mg/kg in any 24 hour period.</p><p>However, if the option to infuse intravenously is not available and if the intramuscular route is used the normal dosage is 2 g for an adult and 1g for a child, administered as a single intramuscular dose.</p><p>The decision to discontinue Froxa therapy must be a clinical decision; however, the following suggested criteria are believed to represent appropriate requirements for the cessation of Froxa. Chelation therapy should be continued until all of the following criteria are satisfied:</p><p>&bull; the patient must be free of signs and symptoms of systemic iron poisoning (e.g. no acidosis, no worsening hepatoxicity),</p><p>&bull; ideally, a corrected serum iron level should be normal or low (when iron level falls below 100 micro g/dL). Given that laboratories cannot measure serum iron concentrations accurately in the presence of Froxa, it is acceptable to discontinue Froxa when all other criteria are met if the measured serum iron concentration is not elevated.</p><p>&bull; Repeat abdominal radiograph test should be obtained in patients who initially demonstrated multiple radio-opacities to ensure they have disappeared before Froxa is discontinued because they serve as a marker for continued iron absorption,</p><p>&bull; If the patient initially developed vin-rose coloured urine with Froxa therapy, it seems reasonable that urine colour should return to normal before halting Froxa (absence of vin-rose urine is not sufficient by itself to indicate discontinuation of Froxa).</p><p>The effectiveness of treatment is dependent on an adequate urine output in order that the iron complex (ferrioxamine) is excreted from the body. Therefore if oliguria or anuria develop, peritoneal dialysis or haemodialysis may become necessary to remove ferrioxamine.</p><p>It should be noted that the serum iron level may rise sharply when the iron is released from the tissues.</p><p>Theoretically 100 mg Froxa can chelate 8.5 mg of ferric iron.</p><p><strong>Chronic Iron Overload</strong></p><p>The main aim of therapy in well-controlled patients is to maintain an iron balance and prevent haemosiderosis, whilst in overloaded patients a negative iron balance is desirable in order to deplete the increased iron stores and to prevent the toxic effects of iron.</p><p><em>Adults and children:</em></p><p>Froxa therapy should be commenced after the first 10- 20 blood transfusions, or when there is evidence from clinical monitoring that chronic iron overload is present (e.g. serum ferritin &gt;1000 ng/mL. The dose and mode of administration should be individually adapted according to the degree of iron overload.</p><p>Growth retardation may result from iron overload or excessive Froxa doses. If chelation is started before 3 years of age growth must be monitored carefully and the mean daily dose should not exceed 40mg/kg. (see section 4.4 <strong>Special warnings and precautions for use</strong>).</p><p><em>Dose:</em></p><p>The lowest effective dose should be used. The average daily dose will probably lie between 20 and 60 mg/kg/day. Patients with serum ferritin levels of &lt; 2000 ng/mL should require about 25 mg/kg/day, and those with levels between 2000 and 3000 ng/mL about 35 mg/kg/day. Higher doses should only be employed if the benefit for the patient outweighs the risk of unwanted effects.</p><p>Patients with higher serum ferritin may require up to 55 mg/kg/day. It is inadvisable to regularly exceed an average daily dose of 50 mg/kg/day except when very intensive chelation is needed in patients who have completed growth. If ferritin values fall below 1000 ng/mL, the risk of Froxa toxicity increases; it is important to monitor these patients particularly carefully and perhaps to consider lowering the total weekly dose.</p><p>To assess the chelation therapy, 24 hour urinary iron excretion should initially be monitored daily. Starting with a dose of 500 mg daily the dose should be raised until a plateau of iron excretion is reached. Once the appropriate dose has been established, urinary iron excretion rates can be assessed at intervals of a few weeks.</p><p>Alternatively the mean daily dose may be adjusted based on ferritin level in order to keep the therapeutic index below 0.025 (i.e. the mean daily dose (mg/kg) of Froxa divided by the serum ferritin level (micro g/L) should be below 0.025). The therapeutic index is a valuable tool in protecting the patient from excess chelation, but it is not a substitute for careful clinical monitoring.</p><p><em>Mode of administration: </em></p><p>Slow subcutaneous infusion using a portable, light-weight, infusion pump over a period of 8-12 hours is effective and particularly convenient for ambulant patients. It may be possible to achieve a further increase in iron excretion by infusing the same daily dose over a 24 hour period. Froxa should normally be used with the pump 5-7 times a week. Froxa is not formulated to support subcutaneous bolus injection.</p><p>Since the subcutaneous infusions are more effective, intramuscular injections are given only when subcutaneous infusions are not feasible.</p><p><em>Elderly </em></p><p>Clinical studies of Froxa did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently compared to younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy&#39; (see sections 4.4 <strong>Special warnings and precautions for use</strong> and 4.8 <strong>Undesirable effects</strong>).</p><p><em>Hepatic impairment </em></p><p>No studies have been performed in patients with hepatic impairment.</p><p><em>Intravenous infusion during blood transfusion</em></p><p>The availability of an intravenous line during blood transfusions makes it possible to administer an intravenous infusion, e.g. in patients who comply poorly with and/or do not tolerate subcutaneous infusions.<em> </em></p><p>The Froxa solution should not be put directly into the blood bag but may be added to the blood line by means of a &ldquo;Y&rdquo; adaptor located near to venous site of injection. The patient&#39;s pump should be used to administer Froxa as usual. Because of the limited amount of drug that can be administered by IV infusion during blood transfusion, the clinical benefit of this mode of administration is limited. Patients and nurses should be warned against accelerating the infusion, as an intravenous bolus of Froxa may lead to flushing, hypotension and circulatory collapse (see section 4.4 <strong>Special warnings and precautions for use</strong>).</p><p>Continuous intravenous infusion is recommended for patients incapable of continuing subcutaneous infusions and in those who have cardiac problems secondary to iron overload. 24 hour urinary iron excretion should be measured regularly where intensive chelation (i.v.) is required, and the dose adjusted accordingly. Implanted intravenous systems can be used when intensive chelation is carried out.</p><p>Care should be taken when flushing the line to avoid a sudden infusion of residual Froxa which may be present in the dead space of the line, as this may lead to flushing, hypotension and circulatory collapse (see section 4.4 <strong>Special</strong> <strong>warnings and precautions</strong> <strong>for use</strong>).</p><p><strong>Diagnosis of iron storage disease and certain anaemias </strong></p><p>The Froxa test for iron overload is based on the principle that normal subjects do not excrete more than a fraction of a milligram of iron in their urine daily, and that a standard intramuscular injection of 500 mg of Froxa will not increase this above 1 mg of iron (18 micro mol). In iron storage diseases, however, the increase may be well over 1.5 mg (27 micro mol). It should be borne in mind that the test only yields reliable results when renal function is normal.</p><p>Froxa is administered as 500 mg intramuscular injection. Urine is then collected for a period of 6 hours and its iron content determined.</p><p>Excretion of 1-1.5 mg (18-27 micro mol) of iron during this 6-hour period is suggestive of iron overload; values greater than 1.5 mg (27 micro mol) can be regarded as pathological.</p><p><strong>Treatment for aluminium overload in patients with end stage renal failure</strong></p><p>Patients should receive Froxa if:</p><p>- They have symptoms or evidence of organ impairment due to aluminium overload</p><p>- they are asymptomatic but their serum aluminium levels are consistently above 60 ng/mL and associated with a positive Froxa test (see below), particularly if a bone biopsy provides evidence of aluminium related bone disease.</p><p>The iron and aluminium complexes of Froxa are dialysable. In patients with renal failure their elimination will be increased by dialysis.</p><p><em>Adults and children:</em></p><p>Patients on maintenance haemodialysis or hemofiltration: 5 mg/kg once a week. Patients with post-desferrioxamine test serum aluminium levels up to 300 ng/mL: Froxa should be given as a slow i.v. infusion during the last 60 minutes of a dialysis session (to reduce loss of free drug in the dialysate). Patients with a post-desferrioxamine test serum aluminium value above 300 ng/ml: Froxa should be administered by slow i.v. infusion 5 hours prior to the dialysis session.</p><p>Four weeks after the completion of a three month course of Froxa treatment a Froxa infusion test should be performed, followed by a second test 1 month later. Serum aluminium increases of less than 50ng/mL above baseline measured in 2 successive infusion tests indicate that further Froxa treatment is not necessary.</p><p><em>Patients on CAPD or CCPD:</em></p><p>5 mg/kg once a week prior to the final exchange of the day. It is recommended that the intraperitoneal route be used in these patients. However, Froxa can also be given i.m., by slow infusion i.v. or s.c.</p><p><strong>Diagnosis of aluminium overload in patients with end stage renal failure </strong></p><p>A Froxa infusion test is recommended in patients with serum aluminium levels &gt; 60ng/mL associated with serum ferritin levels &gt;100 ng/mL.</p><p>Just before starting the haemodialysis session, a blood sample is taken to determine the baseline level serum aluminium level.</p><p>During the last 60 minutes of the haemodialysis session a 5mg/kg dose is given as a slow intravenous infusion.</p><p>At the start of the next haemodialysis session (i.e. 44 hours after the aforementioned Froxa infusion) the second blood sample is taken to determine the serum aluminium level once more.</p><p>An increase in serum aluminium above baseline of more than 150 ng/mL is suggestive of aluminium overload. It should be noted that a negative test does not completely exclude the possibility of aluminium overload.</p><p>Theoretically, 100 mg Froxa can bind 4.1 mg Al<sup>+++</sup>.</p><p><strong>Use in the elderly</strong></p><p>No special dosage regime is necessary but concurrent renal insufficiency should be taken into account.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to desferrioxamine mesilate unless the patients can be desensitised.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Renal impairment</em></p><p>Froxa&nbsp; should be used with caution in patients with renal impairment since the metal complexes are excreted via the kidneys. In these patients, dialysis will increase the elimination of chelated iron and aluminium. Isolated cases of acute renal failure have been reported (see also section 4.8 <strong>Undesirable effects</strong>). Monitoring patients for changes in renal function (e.g. increased serum creatinine) should be considered.</p><p><em>Neurological impairment</em></p><p>Used alone Froxa&nbsp; may exacerbate neurological impairment in patients with aluminium-related encephalopathy. This deterioration (manifest as seizures) is probably related to an acute increase in brain aluminium secondary to elevated circulating levels. Pretreatment with clonazepam has been shown to afford protection against such impairment. Also, treatment of aluminium overload may result in decreased serum calcium and aggravation of hyperparathyroidism.</p><p><em>Rapid intravenous infusion</em></p><p>Treatment with Froxa&nbsp; by the intravenous route should only be administered in the form of <u>slow</u> infusions. Rapid intravenous infusion may lead to hypotension and shock (e.g. flushing, tachycardia, circulatory collapse and urticaria).</p><p><em>Instructions for use and handling</em></p><p>Froxa&nbsp; should not be administered s.c. in concentrations and/or doses higher than those recommended as local irritation at the site of administration may occur more frequently.</p><p><em>Infections</em></p><p>Patients suffering from iron overload are particularly susceptible to infection. There have been reports of Froxa&nbsp; promoting some infections such as <em>Yersinia enterocolitica</em> and <em>Y. pseudotuberculosis</em>. If patients develop fever with pharyngitis, diffuse abdominal pain or enteritis/enterocolitis, Froxa&nbsp; therapy should be stopped, and appropriate treatment with antibiotics should be instituted. Froxa&nbsp; therapy may be resumed once the infection has cleared.</p><p>In patients, receiving Froxa&nbsp; for aluminium and/or iron overload there have been rare reports of mucormycosis (a severe fungal infection), some with fatal outcome. If any characteristic signs or symptoms occur Froxa&nbsp; treatment should be discontinued, mycological tests carried out and appropriate treatment immediately instituted. Mucormycosis has been reported to occur in dialysis patients not receiving Froxa , thus no causal link with the use of the drug has been established.</p><p><em>Visual and hearing impairment</em></p><p>Disturbances of vision and hearing have been reported during prolonged Froxa&nbsp; therapy. In particular, this has occurred in patients on higher than recommended therapy or in patients with low serum ferritin levels. Patients with renal failure who are receiving maintenance dialysis and have low ferritin levels may be particularly prone to adverse reactions, visual symptoms having been reported after single doses of Froxa . Therefore, ophthalmological and audiological tests should be carried out both prior to the institution of therapy with Froxa&nbsp; and at 3-monthly intervals during treatment particularly if ferritin levels are low. By keeping the ratio of the mean daily dose (mg/kg of Froxa l) divided by the serum ferritin (micro g/L) below 0.025 the risk of audiometric abnormalities may be reduced in thalassaemia patients. A detailed ophthalmological assessment is recommended (visual field measurements, fundoscopy, and colour vision testing using pseudoisochromatic plates and the Farnsworth D-15 colour test, slit lamp investigation, visual evoked potential studies).</p><p>If disturbances of vision or hearing do occur, treatment with Froxa&nbsp; should be stopped. Such disturbances are usually reversible. If Froxa&nbsp; therapy is re-instituted later at a lower dosage, close monitoring of ophthalmological/auditory function should be carried out with due regard to the risk-benefit ratio.</p><p><em>Paediatrics: growth retardation</em></p><p>The use of inappropriately high doses of Froxa&nbsp; in patients with low ferritin levels or young children (&lt;3 years at commencement of treatment) has also been associated with growth retardation; dose reduction has been found to restore the growth rate to pretreatment levels in some cases. Three monthly checks on body weight and height are recommended in children.</p><p>Growth retardation if associated with excessive doses of Froxa&nbsp; must be distinguished from growth retardation from iron overload. Growth retardation from Froxa&nbsp; use is rare if the dose is kept below 40 mg/kg; if growth retardation has been associated with doses above this value, then reduction of the dose may result in return in growth velocity, however, predicted adult height is not attained.</p><p><em>Acute respiratory distress syndrome</em></p><p>Acute respiratory distress syndrome has been described following treatment with excessively high i.v. doses of Froxa&nbsp; in patients with acute iron intoxication, and also in thalassaemic patients (see section 4.8 <strong>Undesirable effects</strong>). The recommended daily doses should therefore not be exceeded.</p><p>It should be noted that desferrioxamine will affect aluminium levels and may necessitate some dosage adjustment of erythropoietin if co-prescribed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oral administration of vitamin C (up to a maximum of 200 mg daily, given in divided doses) may serve to enhance excretion of the iron complex in response to Froxa ; larger doses of vitamin C fail to produce an additional effect. Monitoring of cardiac function is indicated during such combined therapy. Vitamin C should be given only if the patient is receiving Froxa regularly and should not be administered within the first month of Froxa &nbsp;therapy. In patients with severe chronic iron-storage disease undergoing combined treatment with Froxa &nbsp;and high doses of vitamin C (more than 500 mg daily) impairment of cardiac function has been encountered; this proved reversible when the vitamin C was withdrawn. Vitamin C supplements should not, therefore, be given to patients with cardiac failure.</p><p>Froxa should not be used in combination with prochlorperazine (a phenothiazine derivative) since prolonged unconsciousness may result.</p><p>Gallium<sup>67</sup> imaging results may be distorted because of the rapid urinary excretion of Froxa -bound radiolabel. Discontinuation of &nbsp;Froxa &nbsp;48 hours prior to scintigraphy is advised.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Women of child-bearing potential</strong></p><p>In women of child-bearing potential, each case the benefits for the mother must be weighed against the risks for the</p><p>child.</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p>There is a limited amount of data on the use of desferrioxamine in pregnant patients. Studies in animals (rabbits) haveshown reproductive toxicity/teratogenicity (see section 5.3 Preclinical safety data). The risk to the foetus/mother is unknown.</p><p>Froxa should be used during pregnancy only if the expected benefits to the mother outweigh the potential risk to</p><p>the foetus.</p><p>&nbsp;</p><p><strong>Breastfeeding</strong></p><p>It is not known whether Froxa is excreted into the breast milk. Because many drugs are excreted in human milk,</p><p>and because of the potential for serious adverse drug reactions in breast-fed newborns/infants, a decision should be</p><p>made whether to abstain from breast-feeding or to abstain from using the medicinal product, taking into account the</p><p>importance of the medicinal product to the mother</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients experiencing CNS effects such as dizziness or impaired vision or hearing should be warned against driving or operating machinery..</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions (Table 1) are ranked under heading of frequency, the most frequent first, using the following convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &le; 1/100); rare (&ge; 1/10,000 to &le; 1/1,000); very rare (&le; 1/10,000) including isolated reports; not known (cannot be estimated from the available data).</p><p>Some signs and symptoms reported as adverse effects may also be manifestations of the underlying disease (iron and/or aluminium overload).</p><p>Infections and infestations</p><p>Rare: Mucormycosis infections have been reported (see 4.4 Special warnings and precautions for use).</p><p>Very rare: Gastroenteritis yersinia infections have been reported (see 4.4 Special warnings and precautions for use).</p><p>Blood and lymphatic system disorders</p><p>Very rare: blood disorders including thrombocytopenia</p><p>Unknown: leukopenia</p><p>Immune system disorders</p><p>Very rare: anaphylactic shock, anaphylactic reactions, angioneurotic oedema.</p><p>Nervous system disorders</p><p>Very rare: neurological disturbances, including dizziness, precipitation or exacerbation of aluminium-related dialysis encephalopathy, neuropathy peripheral, paraesthesia (see 4.4 Special warnings and precautions for use).</p><p>Unknown: convulsion.</p><p>Eye disorders</p><p>Rare: loss of vision, scotoma, retinal degeneration, optic neuritis, cataracts (visual acuity decreased), blurred vision, night blindness, visual field defects, chromatopsia (impairment of colour vision), corneal opacities, (see 4.4. Special warnings and precautions for use). Eye disorders are rare, except if high doses are given.</p><p>Ear and labyrinth disorders</p><p>Uncommon: deafness neurosensory, tinnitus (see 4.4. Special warnings and precautions for use). Keeping</p><p>within dose guidelines helps minimise risk of hearing side effects.</p><p>Vascular disorders</p><p>Rare: hypotension, tachycardia and shock if precautions for administration are not adhered to (see 4.2 Posology and method of administration and 4.4 Special warnings and precautions for use).</p><p>Respiratory, thoracic and mediastinal disorders</p><p>Very rare: acute respiratory distress lung infiltration (see 4.4 Special warnings and precautions for use).</p><p>Gastrointestinal disorders</p><p>Very rare: diarrhoea.</p><p>Skin and subcutaneous tissue disorders</p><p>Very rare: rash generalised.</p><p>Musculoskeletal and connective tissue disorders</p><p>Common: growth retardation and bone disorder (e.g. metaphyseal dysplasia) are common in chelated patients given doses of 60 mg/kg, especially those who begin iron chelation in the first three years of life. If doses are kept to 40 mg/kg or below, the risk is considerably reduced (see 4.4 Special warnings and precautions for use).</p><p>Unknown: muscle spasms.</p><p>Renal and urinary disorders</p><p>Unknown: acute renal failure, renal tubular disorder, blood creatinine increased (see 4.4 Special warnings and precautions for use and section 4.9 Overdose).</p><p>Special remarks</p><p>At the injection site pain, swelling, infiltration, erythema, pruritus and eschar/crust are very common; vesicles, local oedema and burning are uncommon reactions. The local manifestations may be accompanied by systemic reactions like arthralgia/myalgia (very common), headache (common), urticaria (common), nausea (common), pyrexia (common), vomiting (uncommon), or abdominal pain (uncommon) or asthma (uncommon).</p><p>Excretion of the iron complex may cause reddish-brown discoloration of the urine.</p><p>Convulsion has been mainly reported in dialysed patients with aluminium overload.</p><p><strong>Patients treated for chronic aluminum overload</strong></p><p>Froxa chelation therapy aluminum overload may result in hypocalcemia and aggravation of hyperparathyroidism (see section 4.4 Special warnings and precautions for use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Froxa is usually administered parenterally and acute poisoning is unlikely to occur.</p><p>Signs and symptoms: tachycardia, hypotension and gastro-intestinal symptoms have occasionally occurred in patients who received an overdose of Froxa. Accidental administration of Froxa by the i.v. route may be associated with acute but transient loss of vision, aphasia, agitation, headache, nausea, bradycardia, hypotension and acute renal failure (see section 4.8 Undesirable effects).</p><p>Acute respiratory distress syndrome has been described following treatment with excessively high i.v. doses of Froxa in patients with acute iron intoxication, and also in thalassemic patients (see also section 4.4 Special warnings and precautions for use).</p><p>Treatment: there is no specific antidote to Froxa but signs and symptoms may be eliminated by reducing the dosage and Froxa is dialysable. Appropriate supportive therapy should be instituted.</p><p><strong><em>&nbsp;</em></strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Chelating agent (ATC code: V03AC01)</p><p>Froxa is a chelating agent for trivalent iron and aluminium ions; the resulting chelates (ferrioxamine and</p><p>aluminoxamine) are stable and non-toxic. Neither chelate undergoes intestinal absorption, and any formed</p><p>systemically as a result of parenteral administration is rapidly excreted via the kidneys without deleterious effects.</p><p>Froxa takes up iron either free or bound to ferritin and haemosiderin. Similarly it mobilises and chelates tissue bound aluminium. It does not remove iron from haemin containing substances including haemoglobin and transferrin.</p><p>Since both ferrioxamine and aluminoxamine are completely excreted, Froxa promotes the excretion of iron and aluminium in urine and faeces, thus reducing pathological iron or aluminium deposits in the organs and tissues .</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>Desferrioxamine is rapidly absorbed after intramuscular bolus injection or slow subcutaneous infusion, but is only</p><p>poorly absorbed from the gastrointestinal tract in the presence of intact mucosa.</p><p>During peritoneal dialysis desferrioxamine is absorbed if administered in the dialysis fluid.</p><p><strong>Distribution</strong></p><p>In healthy volunteers peak plasma concentrations of desferrioxamine (15.5 micro mol/L (87 micro g/mL)) were</p><p>measured 30 minutes after an intramuscular injection of 10 mg/kg desferrioxamine. One hour after injection the peak concentration of ferrioxamine was 3.7 micro mol/L (2.3 micro g/mL). Less than 10% of desferrioxamine is bound to serum proteins in vitro.</p><p>Biotransformation</p><p>Four metabolites of desferrioxamine were isolated from the urine of patients with iron overload. The following</p><p>biotransformation reactions were found to occur with desferrioxamine: transamination and oxidation yielding an acid metabolite, beta-oxidation also yielding an acid metabolite, decarboxylation and N-hydroxylation yielding neutral metabolites.</p><p><strong>Elimination</strong></p><p>Both desferrioxamine and ferrioxamine a biphasic elimination after intramuscular injection in healthy volunteers; for</p><p>desferrioxamine the apparent distribution half-life is 1 hour, and for ferrioxamine 2.4 hours. The apparent terminal</p><p>half-life is 6 hours for both. Within six hours of injection, 22% of the dose appears in the urine as desferrioxamine and 1% as ferrioxamine.</p><p><strong>Characteristics in patients</strong></p><p>In patients with haemochromatosis peak plasma levels of 7.0 micro mol/L (3.9 micro g/mL) were measured for</p><p>desferrioxamine, and 15.7 micro mol/L (9.6 micro g/mL) for ferrioxamine, 1 hour after an intramuscular injection of 10mg/kg desferrioxamine. These patients eliminated desferrioxamine and ferrioxamine with half-lives of 5.6 and 4.6</p><p>hours respectively. Six hours after the injection 17% of the dose was excreted in the urine as desferrioxamine and</p><p>12% as ferrioxamine.</p><p>In patients dialysed for renal failure who received 40 mg/kg desferrioxamine infused i.v. within 1 hour, the plasma</p><p>concentration at the end of the infusion was 152 micro mol/L (85.2 micro g/mL) when the infusion was given between dialysis sessions. Plasma concentrations of desferrioxamine were between 13% and 27% lower when the infusion was administered during dialysis. Concentrations of ferrioxamine were in all cases approximately 7.0 micro mol/L (4.3 micro g/mL) with concomitant aluminoxamine levels of 2-3 micro mol/litre (1.2-1.8 micro g/mL). After the infusion was discontinued, the plasma concentrations of desferrioxamine decreased rapidly with a half-life of 20 minutes. A smaller fraction of the dose was eliminated with a longer half-life of 14 hours. Plasma concentrations of aluminoxamine continued to increase for up to 48 hours post-infusion and reached values of approximately 7 micro mol/L (4 micro g/mL). Following dialysis the plasma concentration of aluminoxamine fell to 2.2 micro mol/L (1.3 micro g/mL), indicating that the aluminoxamine complex is dialysable.</p><p>In patients with thalassaemia continuous intravenous infusion of 50mg/kg/24h of desferrioxamine resulted in plasma</p><p>steady state levels of desferrioxamine of 7.4 micro mol/L. Elimination of desferrioxamine from plasma was biphasic</p><p>with a mean distribution half-life of 0.28 hours and an apparent terminal half-life of 3.0 hours. The total plasma</p><p>clearance was 0.5 L/h/kg and the volume of distribution at steady state was estimated at 1.35 L/kg. Exposure to the</p><p>main iron binding metabolite was around 54% of that of desferrioxamine in terms of AUC. The apparent</p><p>monoexponential elimination half-life of the metabolite was 1.3 hours<strong><em>.</em></strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>NA </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Water for Injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Heparin solution for injection.</p><p>Physiological saline (0.9%) should not be used as a solvent for the dry substance. However, it may be used for further dilution after reconstitution of the Froxa solution with water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Two years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Reconstituted solution: Single use only.</p><p>From a microbiological point of view, the product should be used immediately after reconstitution (commencement of treatment within 3 hours). When the reconstitution is carried out under validated aseptic conditions the reconstituted solution may be stored for a maximum of 24 hours at room temperature (30&deg;C or below) before administration. If not used immediately, in-use storage times and conditions prior to administration are the responsibility of the user. Unused solution should be discarded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vial 6R</p><p>Bromobutyl rubber stopper 20 mm lyophilized</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None stated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma Saudi,
Riyadh, Kingdome Saudi Arabia.
medical-ksa@mspharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Feb-2020
SPC-022-0719-00

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>